Please Wait
Applying Filters...
menu
    • menu
    Trusted Global CDMO Partner Delivering End-to-End Pharma Manufacturing & Development Solutions.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Ever Pharma, highly specialized CDMO in producing complex injectables including high potency & controlled substances, suspensions, etc.

    Virtual Booth

    Contact Supplier

    Topscience Biotech specializes in R&D, production, and sales of Sodium Hyaluronate, focusing on Medical and Pharmaceutical Grade HA.

    Virtual Booth

    Contact Supplier

    With Virupaksha, you get a quality product with on-time delivery.

    Virtual Booth

    Contact Supplier

    LEBSA- Your strategic API source for niche molecules.

    Virtual Booth

    Contact Supplier

    Menu

    Olaratumab

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Telix Doses First Patient in ZOLAR Trial of TLX300-CDx in Sarcoma
    Telix Doses First Patient in ZOLAR Trial of TLX300-CDx in Sarcoma

    01 Apr 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/04/01/3053755/0/en/Telix-Announces-First-Patient-Dosed-in-First-in-Human-ZOLAR-Trial-of-TLX300-CDx-in-Advanced-Soft-Tissue-Sarcoma.html

    GLOBENEWSWIRE
    01 Apr 2025
    Share Share
    Olaratumab Antibody Licensed from Lilly Demonstrates Proof of Concept
    Olaratumab Antibody Licensed from Lilly Demonstrates Proof of Concept

    17 Apr 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/olaratumab-antibody-licensed-from-lilly-demonstrates-proof-of-concept-as-a-theranostic-radiopharmaceutical-301798405.html

    PR NEWSWIRE
    17 Apr 2023
    Share Share
    Lilly inks licensing deal for cancer therapy with Australian biotech Telix
    Lilly inks licensing deal for cancer therapy with Australian biotech Telix

    12 Apr 2022

    // D. Lokuwithania SEEKING ALPHA

    https://seekingalpha.com/news/3822270-eli-lilly-in-pact-with-australian-biotech-telix-for-cancer-therapy

    D. Lokuwithania SEEKING ALPHA
    12 Apr 2022
    Share Share
    Lilly inks licensing deal for cancer therapy with Australian biotech Telix
    Lilly inks licensing deal for cancer therapy with Australian biotech Telix

    11 Apr 2022

    // Dulan Lokuwithania SEEKING ALPHA

    https://seekingalpha.com/news/3822270-eli-lilly-in-pact-with-australian-biotech-telix-for-cancer-therapy

    Dulan Lokuwithania SEEKING ALPHA
    11 Apr 2022
    Share Share
    Keytruda is First to Add Indications Under TGA’s Provisional Approval Pathway
    Keytruda is First to Add Indications Under TGA’s Provisional Approval Pathway

    18 Jul 2019

    // Zachary Brennan RAPS

    https://www.raps.org/news-and-articles/news-articles/2019/7/mercks-keytruda-is-first-to-add-indications-under

    Zachary Brennan RAPS
    18 Jul 2019
    Share Share
    Lilly Bio-Medicines chief Christi Shaw steps aside, leaving key launches behind
    Lilly Bio-Medicines chief Christi Shaw steps aside, leaving key launches behind

    11 Jul 2019

    // Eric Sagonowsky FIERCE PHARMA

    https://www.fiercepharma.com/pharma/amid-important-launches-lilly-s-bio-medicines-head-shaw-steps-aside

    Eric Sagonowsky FIERCE PHARMA
    11 Jul 2019
    Share Share